1 Reason I'll Never Sell Vertex Pharmaceuticals Stock
Vertex Pharmaceuticals (NASDAQ: VRTX) has proven itself to be an excellent long-term investment, advancing 91% over the past five years. This is as the company has delivered steady growth in revenue thanks to a market-leading franchise.
Vertex is the global leader in cystic fibrosis (CF) drugs, and the company's products have both revolutionized the treatment of this disease and generated blockbuster revenue. This biotech player also has expanded its research into other disease areas and scored two wins in recent years, with approvals of Casgevy for blood disorders and Journavx for pain management.
So, even though Vertex stock may not soar every year, I'm optimistic about the stock's long-term prospects. Here's one reason I'll never sell this biotech giant.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Reines Buy-Sentiment für Vertex Pharmaceuticals Inc., keine Sell-Einschätzungen in Sicht.
Eine deutliche Steigerung um mehr als 20% ist für Vertex Pharmaceuticals Inc. mit einem Kursziel von 461 € gegenüber 374.9 € zu erwarten.
